Postpartum Hemorrhage Treatment Market: By Drug Type, Ergot Alkaloids, Tranexamic acid, Pabal, Carboprost, Others), By Route of Administration, By Distribution Channel and Region
Postpartum hemorrhage treatment market size was valued at US$ 962.34 million in 2023, growing at a CAGR of 5.3% during the forecast period 2024-2030. The Postpartum Hemorrhage (PPH) is an obstetric hemorrhagic condition that is a prime reason for maternal mortality. In postpartum hemorrhagic condition patient loss about 500mL blood in vaginal delivery or approximately 1000mL blood after cesarean delivery. It is categorized into two types namely, primary postpartum hemorrhage and secondary postpartum hemorrhage. Most commonly used drugs in postpartum hemorrhage are oxytocin and misoprostol. Rise in prevalence of multiple pregnancies, inverted uterus, and other pregnancy complication, increase in risk factors for postpartum hemorrhage such as uterine atony, rise in R&D for the innovation of newer drugs, product pipeline of postpartum hemorrhage drugs, and rise in anemia in pregnant woman are anticipated to fuel the postpartum hemorrhage treatment market. However, adverse effects associated with drugs, stringent regulatory guidelines for newer drug approval, and lack of awareness about drugs in underdeveloped countries may impede the growth of postpartum hemorrhage treatment market.
Study Period
2024-2030Base Year
2023CAGR
5.3%Largest Market
EuropeFastest Growing Market
North America
Increasing pregnancy problems like inverted uterus, big size of the baby and multiple pregnancies are some key drivers of the market growth. Technological development like capability of the devices to soothe the patients condition until permanent treatment is given is propelling the market growth. The Support from healthcare organizations, Rising pregnancy complications. Dearth of trained healthcare providers, High cost of the devices.
Geographically, global postpartum hemorrhage treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa regions. North America is growth attributed to high awareness about postpartum hemorrhage drugs among physicians, better availability of products, and increase in healthcare expenditure. Europe is poised to grow due to increase in complicated pregnancy cases such as severe preeclampsia, high existence of anemia in pregnant women, and high awareness about postpartum hemorrhage treatment among healthcare professionals. Asia Pacific has a significant share, which is attributed to increase in number of childbirths in India and China, rise in prevalence of postpartum hemorrhage in South Korea, and rise in R&D activities for the innovation of newer drugs. Latin America expected to account for notable share owing to rise in pre-mature labors in Brazil. Middle East and Africa growth driven by rise in prevalence of postpartum hemorrhage cases due to malnutrition in pregnant women, multiple gestations in Saudi Arabia women are expected to boost the market in the region.
Different technological advances in the healthcare service provider industries in Asia Pacific are anticipated to provide growth opportunities for the market players working in the market. Increasing prevalence of postpartum hemorrhage is impelling the market growth. North America obtained the huge revenue share in the year 2017. Increasing government support and new product launchings by key players in the market are fueling the market growth.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 962.34 million |
|
Market CAGR |
5.3% |
|
By Drug Type |
|
|
By Route Administration |
|
|
By Distribution Channel |
|
Download Free Sample Report
The global postpartum hemorrhage treatment market size was valued at US$ 962.34 million in 2023 and is projected to grow at a CAGR of 5.3%
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
| 1. Executive Summary |
| 2. Global Postpartum Hemorrhage Treatment Market Introduction |
| 2.1.Global Postpartum Hemorrhage Treatment Market - Taxonomy |
| 2.2.Global Postpartum Hemorrhage Treatment Market - Definitions |
| 2.2.1.Drug Type |
| 2.2.2.Route Administration |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3. Global Postpartum Hemorrhage Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Postpartum Hemorrhage Treatment Market Analysis, 2019- -2030 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Postpartum Hemorrhage Treatment Market By Drug Type, 2019- -2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Oxytocin |
| 5.1.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Prostaglandins (Dinoprostone, Misoprostol) |
| 5.2.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Ergot Alkaloids (Ergometrine, Methyl Ergonovine) |
| 5.3.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Tranexamic acid |
| 5.4.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Pabal |
| 5.5.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Carboprost |
| 5.6.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Others |
| 5.7.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 6. Global Postpartum Hemorrhage Treatment Market By Route Administration, 2019- -2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Oral |
| 6.1.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Parenteral |
| 6.2.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7. Global Postpartum Hemorrhage Treatment Market By Distribution Channel, 2019- -2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospital Pharmacies |
| 7.1.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacies |
| 7.2.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Online Pharmacies |
| 7.3.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Global Postpartum Hemorrhage Treatment Market By Region, 2019- -2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9. North America Postpartum Hemorrhage Treatment Market ,2019- -2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Drug Type Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Oxytocin |
| 9.1.2.Prostaglandins (Dinoprostone, Misoprostol) |
| 9.1.3.Ergot Alkaloids (Ergometrine, Methyl Ergonovine) |
| 9.1.4.Tranexamic acid |
| 9.1.5.Pabal |
| 9.1.6.Carboprost |
| 9.1.7.Others |
| 9.2. Route Administration Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Oral |
| 9.2.2.Parenteral |
| 9.3. Distribution Channel Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital Pharmacies |
| 9.3.2.Retail Pharmacies |
| 9.3.3.Online Pharmacies |
| 9.4. Country Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10. Europe Postpartum Hemorrhage Treatment Market ,2019- -2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Oxytocin |
| 10.1.2.Prostaglandins (Dinoprostone, Misoprostol) |
| 10.1.3.Ergot Alkaloids (Ergometrine, Methyl Ergonovine) |
| 10.1.4.Tranexamic acid |
| 10.1.5.Pabal |
| 10.1.6.Carboprost |
| 10.1.7.Others |
| 10.2. Route Administration Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Oral |
| 10.2.2.Parenteral |
| 10.3. Distribution Channel Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital Pharmacies |
| 10.3.2.Retail Pharmacies |
| 10.3.3.Online Pharmacies |
| 10.4. Country Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11. Asia Pacific (APAC) Postpartum Hemorrhage Treatment Market ,2019- -2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Oxytocin |
| 11.1.2.Prostaglandins (Dinoprostone, Misoprostol) |
| 11.1.3.Ergot Alkaloids (Ergometrine, Methyl Ergonovine) |
| 11.1.4.Tranexamic acid |
| 11.1.5.Pabal |
| 11.1.6.Carboprost |
| 11.1.7.Others |
| 11.2. Route Administration Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Oral |
| 11.2.2.Parenteral |
| 11.3. Distribution Channel Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital Pharmacies |
| 11.3.2.Retail Pharmacies |
| 11.3.3.Online Pharmacies |
| 11.4. Country Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12. Middle East and Africa (MEA) Postpartum Hemorrhage Treatment Market ,2019- -2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Oxytocin |
| 12.1.2.Prostaglandins (Dinoprostone, Misoprostol) |
| 12.1.3.Ergot Alkaloids (Ergometrine, Methyl Ergonovine) |
| 12.1.4.Tranexamic acid |
| 12.1.5.Pabal |
| 12.1.6.Carboprost |
| 12.1.7.Others |
| 12.2. Route Administration Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Oral |
| 12.2.2.Parenteral |
| 12.3. Distribution Channel Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital Pharmacies |
| 12.3.2.Retail Pharmacies |
| 12.3.3.Online Pharmacies |
| 12.4. Country Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13. Latin America Postpartum Hemorrhage Treatment Market ,2019- -2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Oxytocin |
| 13.1.2.Prostaglandins (Dinoprostone, Misoprostol) |
| 13.1.3.Ergot Alkaloids (Ergometrine, Methyl Ergonovine) |
| 13.1.4.Tranexamic acid |
| 13.1.5.Pabal |
| 13.1.6.Carboprost |
| 13.1.7.Others |
| 13.2. Route Administration Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Oral |
| 13.2.2.Parenteral |
| 13.3. Distribution Channel Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital Pharmacies |
| 13.3.2.Retail Pharmacies |
| 13.3.3.Online Pharmacies |
| 13.4. Country Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Novartis AG (Switzerland) |
| 14.2.2.Fresenius Kabi AG (Germany) |
| 14.2.3.Pfizer, Inc. (U.S.) |
| 14.2.4.GlaxoSmithKline Plc (U.K.) |
| 14.2.5.Ferring B.V. (Switzerland) |
| 14.2.6.Cipla Inc. (India) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
